ClinicalTrials.gg
CompletedNCT04644003Updated Nov 8, 2024Results posted

Safety, Tolerability and Pharmacokinetics Study of STP1 in a Subgroup of Patients With Autism Spectrum Disorder (ASD)

A Phase 1 interventional study of STP1 and Placebo in Autism Spectrum Disorder, sponsored by Stalicla SA. Completed at 1 site in United States. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2024-11-08.

Sponsored by Stalicla SA · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 773 studies in Autism Spectrum Disorder with a site in United States — 163 open to participants now, 203 under way, 9 of them phase 3. Autism Spectrum Disorder · United States.

Enrollment
559th of 658
12 · median 50
Started
2020
with 44 others
Phase 1
44 of 773
8 open now
Registered
454th of 773
by date

Among the 773 studies in Autism Spectrum Disorder with a site in United States, this one is the 559th largest by enrollment of the 658 interventional ones that give a count, is one of 45 that started in 2020, is one of 44 in phase 1, and was the 454th registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

163 of the 773 studies in Autism Spectrum Disorder with a site in United States are open now. Recruiting first, the newest first:

158 more — sign in →

All 163 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 773 studies in Autism Spectrum Disorder with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate safety and tolerability in a subgroup of patients with Autism Spectrum Disorder (ASD). In addition, Pharmacokinetics and Pharmacodynamics, as well as efficacy of STP1 are being explored.

Read the detailed description

After obtaining written informed consent, those patients who are deemed eligible for the study, will be randomized on Day 1, in a double-blinded manner, in a 3:1ratio to receive either oral STP1 (twice daily) or placebo (twice daily). The total study duration is 6 weeks, including a screening phase of up to 2 weeks, a treatment phase of 2 weeks and a post-treatment follow-up phase of 2 weeks.

03

Conditions studied

  • Autism Spectrum Disorder

Keywords

  • ASD
  • Autism Spectrum Disorder
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or female individuals, between 18 and 40 years, diagnosed of ASD.
  2. Patients will be assessed for specific developmental anthropometric \& anatomical criteria as well as personal and family medical history as assessed by the ASD-Phen1 semi structured interview form.
  3. Patients must have a parent or reliable caregiver who can provide information about the pre-natal period and early developmental period, as required by the protocol.
  4. Patient and/or parent or legal guardian willing and consenting to participate.
  5. Patients with ASD and comorbid seizure disorder should be seizure-free for at least 6 months prior to screening.
  6. Before enrolling in the study, subjects must agree to use double-barrier methods if they engage in intercourse.

Key Exclusion Criteria:

  1. Patients with an identified genetic cause of ASD in their medical record will be excluded from the study.
  2. History of traumatic head injury, cerebrovascular disorder, congestive heart failure, hepatic or renal disease.
  3. Thrombocytopenia.
  4. Type 1 Diabetes Mellitus or uncontrolled type 2 Diabetes Mellitus, or latent diabetes of the adult.
  5. A significant risk for suicidal behavior.
  6. Initiation of, or a major change in psychological / behavioral intervention within 4 weeks prior to randomization.
  7. Patient with any active infection.
  8. Systolic blood pressure (SBP) \<80 mmHg or diastolic blood pressure (DBP) \<40 mmHg or a drop in SBP of ≥20 mm Hg, or in DBP of ≥10 mm Hg, during the orthostatic recordings.
  9. (ECG) abnormalities.
  10. Clinically significant abnormal laboratory test.
  11. Active clinically significant disease.
  12. History of .
  13. Pregnant (confirmed by laboratory testing) or lactating female patient.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    STP1 Low Dose

    1 capsule and 1 tablet per intake

    Drug: STP1

  • Experimental
    STP1 High Dose

    1 capsule and 1 tablet per intake

    Drug: STP1

  • Placebo comparator
    Placebo

    1 placebo capsule and 1 placebo tablet per intake

    Drug: Placebo

Interventions

  • DrugSTP1

    STP1 is a combination of two drugs, a phosphodiesterase (PDE) inhibitor and an NKCC1 inhibitor

  • DrugPlacebo

    Placebo medication (capsule and tablet) identical in appearance to active medication

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    Number of Participants with Adverse Events (nature and frequency of non-serious adverse events, serious adverse events and adverse events of special interest).

    Time frame: 14 days

07

Results

Posted Nov 8, 2024

Participant flow

The patient population is defined as ASD-Phen1 based on STALICLA criteria. The number of patients enrolled were 12 subjects with 6 subjects receiving STP1-Low Dose, 3 subjects receiving STP1-High Dose, and 3 subjects receiving placebo. All 12 subjects (100.0%) completed treatment with 0 screen failures.

Participant flow — Overall Study
MilestoneSTP1 Low DoseSTP1 High DosePlacebo
Started633
Completed633
Not completed000

Outcome measures

PrimarySafety and Tolerability

Number of Participants with Adverse Events (nature and frequency of non-serious adverse events, serious adverse events and adverse events of special interest).

Time frame:
14 days
Reported as:
Count of participants · Participants
Safety and Tolerability
ParticipantsSTP1 Low DoseSTP1 High DosePlacebo
Safety and Tolerability633

Adverse events

Collected over The total duration of the study for each participant was up to six weeks divided as follows: a screening phase of two weeks (from Day -14 to Day -1); a double-blind treatment phase of two weeks (from Day 1 to Day 14); and a follow-up phase of two weeks after treatment discontinuation (from Day 15 to Day 28).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
STP1 Low Dose0/6 (0%)0/6 (0%)5/6 (83.3%)
STP1 High Dose0/3 (0%)0/3 (0%)2/3 (66.7%)
Placebo0/3 (0%)0/3 (0%)2/3 (66.7%)
Most frequent other events
Most frequent other events
EventSTP1 Low DoseSTP1 High DosePlacebo
NauseaGastrointestinal disorders1/60/32/3
InfectionInfections and infestations0/61/30/3
Upper respiratory tract infectionInfections and infestations0/61/30/3
DiarrhoeaGastrointestinal disorders1/60/30/3
TrichotillomaniaPsychiatric disorders1/60/30/3
PollakiuriaRenal and urinary disorders1/60/30/3
DyspnoeaRespiratory, thoracic and mediastinal disorders1/60/30/3

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)STP1 Low DoseSTP1 High DosePlaceboTotal
<=18 years0000
Between 18 and 65 years63312
>=65 years0000
Age, Continuous
Age, Continuous(years)STP1 Low DoseSTP1 High DosePlaceboTotal
Mean18.67 ± 0.8219.67 ± 1.5319.67 ± 2.8919.17 ± 1.59
Age, Continuous
Age, Continuous(years)STP1 Low DoseSTP1 High DosePlaceboTotal
Median18.50 (18.0 to 20.0)20.00 (18.0 to 21.0)18.00 (18.0 to 23.0)18.50 (18.0 to 23.0)
Sex: Female, Male
Sex: Female, Male(Participants)STP1 Low DoseSTP1 High DosePlaceboTotal
Female1113
Male5229
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)STP1 Low DoseSTP1 High DosePlaceboTotal
Hispanic or Latino0000
Not Hispanic or Latino63312
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)STP1 Low DoseSTP1 High DosePlaceboTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American1102
White52310
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)STP1 Low DoseSTP1 High DosePlaceboTotal
United States63312
Body Mass Index
Body Mass Index(kg/m^2)STP1 Low DoseSTP1 High DosePlaceboTotal
Mean36.80 ± 5.0237.07 ± 6.8925.17 ± 5.8433.96 ± 7.38
08

Study locations

1 site
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Jan 2022, 13 months.

Results were first posted in Nov 2024, 2 years 9 months after primary completion.

Of 35 phase 1 interventional studies under Autism Spectrum Disorder, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 27. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2020
First posted
Nov 25, 2020
StartActual
Dec 7, 2020
Primary completionActual
Jan 28, 2022
CompletionActual
Jan 28, 2022
Results first posted
Nov 8, 2024
Last update
Nov 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04644003
Lead sponsor
Stalicla SA
Responsible party
Sponsor
First posted
Nov 25, 2020
Start date
Dec 7, 2020
Primary completion
Jan 28, 2022
Completion
Jan 28, 2022
Results posted
Nov 8, 2024
Last update
Nov 8, 2024

Study contacts

Craig Erickson, MD
principal investigator · Children's Hospital Medical Center, Cincinnati

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion